Patient Eligibility Pathways for Remdesivir at UIHC

UIHC currently has access to Remdesivir through a variety of pathways including clinical trial, compassionate use, and the recently announced emergency use authorization. Each of these routes of access has notable limitations and is subject to change at any time. Given the significant supply constraints, UIHC cannot and will not guarantee access to patients even if they appear to meet criteria as described below.

### 1. Evaluate for general inclusion/exclusion criteria. Patients not meeting criteria do not qualify for remdesivir but may remain eligible for alternative agents such as convalescent plasma

| Inclusion: hospitalization, confirmed SARS-CoV-2 by PCR, symptom onset within the past 10 days prior to initiation of remdesivir, radiographic evidence of pulmonary infiltrates | Exclusion: evidence of multiorgan failure, renal failure (CrCl <30 ml/min or continuous hemofiltration), AST or ALT levels > 5x ULN, mechanical ventilation or VV ECMO for ≥5 days prior to initiation of remdesivir, VA ECMO of any duration prior to initiation |

### 2. Identify special patient populations that may qualify for compassionate use program. Compassionate use access may be requested by the primary team in coordination with the antimicrobial stewardship team

- Pediatric patients that are <18 years of age
- Pregnant patients*

### 3. Evaluate for eligibility in ongoing clinical trials. Qualifying patients will need to be consented in coordination with the appropriate study team.

- Moderate disease: $\text{SpO}_2 > 94\%$ on room air at screening, positive SARS-CoV-2 PCR ≤4 days of randomization, CrCl ≥50 ml/min
- Severe disease: $\text{SpO}_2 \leq 94\%$ on room air at screening, positive SARS-CoV-2 PCR ≤4 days of randomization, CrCl ≥50 ml/min

### 4. Evaluate for access through emergency use authorization. If patient is considered eligible, antimicrobial stewardship via pager #1282 (0800 to 2000) must be contacted prior to initiation to assess current inventory.

Patients that meet general inclusion/exclusion criteria but do not fit into a group that may receive through either compassionate use or clinical trial may still receive through emergency use authorization. Patients that are most likely to qualify are patients with borderline renal function (i.e. 30-49 ml/min). However, as clinical trial closes for remdesivir, this patient population will be significantly expanded.

*Given the expected turnaround time for drug through compassionate use, consideration may be made for initiation through emergency use authorization supply (if available).